Cancer omics

From regulatory networks to clinical outcomes

Binhua Tang, Pei Yin Hsu, Hui-ming Huang, Victor X Jin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Current limitation in cancer genomic studies is a lack of the integration of various omics data generated through next generation sequencing technologies, as well as a lack of the sounding and comprehensive epigenomic and genomic information about a particular cancer cell type. In this review, we will discuss main aspects of current genomics research with its application in cancer topics. We will first overview the next-generation sequencing technologies, then outline the major computational approaches, particularly focusing on ChIP-based omics data, and list several remaining open questions facing computational biologists, further present regulatory network analysis inferred from the ChIP-based omics data; finally implicate the clinical outcomes from the network and pathway analysis.

Original languageEnglish (US)
Pages (from-to)277-283
Number of pages7
JournalCancer Letters
Volume340
Issue number2
DOIs
StatePublished - Nov 1 2013

Fingerprint

Technology
Neoplasms
Genomics
Epigenomics
Research

Keywords

  • Cancer omics
  • Clinical outcomes
  • Next generation sequencing
  • Regulatory networks

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cancer omics : From regulatory networks to clinical outcomes. / Tang, Binhua; Hsu, Pei Yin; Huang, Hui-ming; Jin, Victor X.

In: Cancer Letters, Vol. 340, No. 2, 01.11.2013, p. 277-283.

Research output: Contribution to journalArticle

Tang, Binhua ; Hsu, Pei Yin ; Huang, Hui-ming ; Jin, Victor X. / Cancer omics : From regulatory networks to clinical outcomes. In: Cancer Letters. 2013 ; Vol. 340, No. 2. pp. 277-283.
@article{699ce645b02e450db746f51f6e8054eb,
title = "Cancer omics: From regulatory networks to clinical outcomes",
abstract = "Current limitation in cancer genomic studies is a lack of the integration of various omics data generated through next generation sequencing technologies, as well as a lack of the sounding and comprehensive epigenomic and genomic information about a particular cancer cell type. In this review, we will discuss main aspects of current genomics research with its application in cancer topics. We will first overview the next-generation sequencing technologies, then outline the major computational approaches, particularly focusing on ChIP-based omics data, and list several remaining open questions facing computational biologists, further present regulatory network analysis inferred from the ChIP-based omics data; finally implicate the clinical outcomes from the network and pathway analysis.",
keywords = "Cancer omics, Clinical outcomes, Next generation sequencing, Regulatory networks",
author = "Binhua Tang and Hsu, {Pei Yin} and Hui-ming Huang and Jin, {Victor X}",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.canlet.2012.11.033",
language = "English (US)",
volume = "340",
pages = "277--283",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Cancer omics

T2 - From regulatory networks to clinical outcomes

AU - Tang, Binhua

AU - Hsu, Pei Yin

AU - Huang, Hui-ming

AU - Jin, Victor X

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Current limitation in cancer genomic studies is a lack of the integration of various omics data generated through next generation sequencing technologies, as well as a lack of the sounding and comprehensive epigenomic and genomic information about a particular cancer cell type. In this review, we will discuss main aspects of current genomics research with its application in cancer topics. We will first overview the next-generation sequencing technologies, then outline the major computational approaches, particularly focusing on ChIP-based omics data, and list several remaining open questions facing computational biologists, further present regulatory network analysis inferred from the ChIP-based omics data; finally implicate the clinical outcomes from the network and pathway analysis.

AB - Current limitation in cancer genomic studies is a lack of the integration of various omics data generated through next generation sequencing technologies, as well as a lack of the sounding and comprehensive epigenomic and genomic information about a particular cancer cell type. In this review, we will discuss main aspects of current genomics research with its application in cancer topics. We will first overview the next-generation sequencing technologies, then outline the major computational approaches, particularly focusing on ChIP-based omics data, and list several remaining open questions facing computational biologists, further present regulatory network analysis inferred from the ChIP-based omics data; finally implicate the clinical outcomes from the network and pathway analysis.

KW - Cancer omics

KW - Clinical outcomes

KW - Next generation sequencing

KW - Regulatory networks

UR - http://www.scopus.com/inward/record.url?scp=84887616313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887616313&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.11.033

DO - 10.1016/j.canlet.2012.11.033

M3 - Article

VL - 340

SP - 277

EP - 283

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -